Amylyx Pharmaceuticals (NASDAQ:AMLX) Director Sells $831,000.00 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director George Milne, Jr. sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $27.70, for a total transaction of $831,000.00. Following the transaction, the director owned 782,881 shares in the company, valued at $21,685,803.70. This represents a 3.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Amylyx Pharmaceuticals Stock Up 3.5%

NASDAQ:AMLX opened at $28.14 on Friday. The business’s 50-day moving average price is $30.42 and its 200 day moving average price is $21.04. The firm has a market cap of $3.14 billion, a P/E ratio of -19.68 and a beta of -0.10. Amylyx Pharmaceuticals, Inc. has a 52-week low of $10.83 and a 52-week high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Sell-side analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth approximately $158,534,000. Jupiter Topco LLC bought a new position in Amylyx Pharmaceuticals in the second quarter worth $94,014,000. Janus Henderson Group PLC increased its holdings in Amylyx Pharmaceuticals by 11.6% in the 1st quarter. Janus Henderson Group PLC now owns 4,986,073 shares of the company’s stock valued at $69,257,000 after buying an additional 520,201 shares during the period. Commodore Capital LP raised its stake in shares of Amylyx Pharmaceuticals by 38.6% in the 4th quarter. Commodore Capital LP now owns 5,650,000 shares of the company’s stock valued at $68,252,000 after buying an additional 1,574,522 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in Amylyx Pharmaceuticals in the second quarter valued at about $18,912,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Mizuho upped their target price on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. Wolfe Research raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 17th. Citigroup increased their price objective on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Finally, Guggenheim raised their price target on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Amylyx Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $38.86.

Amylyx Pharmaceuticals Company Profile